$SKYE
Skye Bioscience, Inc.

2021 Q4 Form 10-K Financial Statement

#000151655122000004 Filed on March 28, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.348M $4.916M $948.9K
YoY Change 42.09% 13.16% -15.85%
% of Gross Profit
Research & Development $1.113M $2.931M $370.0K
YoY Change 200.91% 50.76% -48.32%
% of Gross Profit
Depreciation & Amortization $24.72K $34.13K $770.00
YoY Change 3110.39% 1723.24% 113.89%
% of Gross Profit
Operating Expenses $2.462M $7.848M $1.319M
YoY Change 86.64% 24.78% -28.46%
Operating Profit -$7.848M
YoY Change 24.78%
Interest Expense -$50.65K $769.2K -$183.2K
YoY Change -72.35% 8.89% -102.47%
% of Operating Profit
Other Income/Expense, Net -$672.4K
YoY Change 148.95%
Pretax Income -$2.512M -$8.520M -$1.502M
YoY Change 67.25% 29.9% -130.96%
Income Tax $500.00 $2.100K $0.00
% Of Pretax Income
Net Earnings -$2.513M -$8.522M -$1.502M
YoY Change 67.29% 29.9% -130.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$5.058K -$0.02 -$5.001K
COMMON SHARES
Basic Shares Outstanding 476.1M shares 406.6M shares
Diluted Shares Outstanding 406.6M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.983M $8.983M $2.469M
YoY Change 263.77% 263.77% 34.94%
Cash & Equivalents $8.983M $2.469M
Short-Term Investments
Other Short-Term Assets $56.87K $629.1K $275.00
YoY Change 20580.0% 222.66% -96.36%
Inventory
Prepaid Expenses $554.2K $190.1K
Receivables
Other Receivables
Total Short-Term Assets $9.612M $9.612M $2.664M
YoY Change 260.76% 260.76% 33.57%
LONG-TERM ASSETS
Property, Plant & Equipment $87.71K $234.7K $7.341K
YoY Change 1094.8% 3097.28% 270.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.309K $8.310K $0.00
YoY Change
Total Long-Term Assets $243.0K $243.0K $7.341K
YoY Change 3210.05% 3210.49% 270.2%
TOTAL ASSETS
Total Short-Term Assets $9.612M $9.612M $2.664M
Total Long-Term Assets $243.0K $243.0K $7.341K
Total Assets $9.855M $9.855M $2.672M
YoY Change 268.87% 268.87% 33.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $897.9K $900.0K $364.3K
YoY Change 146.44% 135.99% 180.67%
Accrued Expenses $601.7K $977.6K $5.455K
YoY Change 10930.8% 222.42% -93.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.975M $1.975M $64.06K
YoY Change 2982.91% 2982.91%
Total Short-Term Liabilities $3.912M $3.912M $787.2K
YoY Change 396.98% 396.98% -18.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $1.434M
YoY Change -100.0% -100.0% 270.41%
Other Long-Term Liabilities $78.70K $78.70K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $78.70K $78.70K $1.434M
YoY Change -94.51% -94.51% 200.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.912M $3.912M $787.2K
Total Long-Term Liabilities $78.70K $78.70K $1.434M
Total Liabilities $3.991M $3.991M $2.221M
YoY Change 79.7% 79.7% 53.31%
SHAREHOLDERS EQUITY
Retained Earnings -$47.26M -$38.73M
YoY Change 22.0% 20.39%
Common Stock $53.12M $39.18M
YoY Change 35.56% 19.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.864M $5.864M $450.8K
YoY Change
Total Liabilities & Shareholders Equity $9.855M $9.855M $2.672M
YoY Change 268.87% 268.87% 33.8%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.513M -$8.522M -$1.502M
YoY Change 67.29% 29.9% -130.96%
Depreciation, Depletion And Amortization $24.72K $34.13K $770.00
YoY Change 3110.39% 1723.24% 113.89%
Cash From Operating Activities -$1.969M -$6.475M -$1.786M
YoY Change 10.24% 6.95% 18.81%
INVESTING ACTIVITIES
Capital Expenditures -$54.04K $90.87K -$7.230K
YoY Change 647.44% 1156.79%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$54.04K -$90.87K -$7.230K
YoY Change 647.44% 1156.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.063M
YoY Change -0.37%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -83.72K $13.08M 38.00K
YoY Change -320.32% 95.19% -98.11%
NET CHANGE
Cash From Operating Activities -1.969M -$6.475M -1.786M
Cash From Investing Activities -54.04K -$90.87K -7.230K
Cash From Financing Activities -83.72K $13.08M 38.00K
Net Change In Cash -2.107M $6.514M -1.755M
YoY Change 20.02% 918.61% -443.72%
FREE CASH FLOW
Cash From Operating Activities -$1.969M -$6.475M -$1.786M
Capital Expenditures -$54.04K $90.87K -$7.230K
Free Cash Flow -$1.915M -$6.566M -$1.779M
YoY Change 7.65% 8.32% 18.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001516551
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-55136
CY2021 dei Entity Registrant Name
EntityRegistrantName
Skye Bioscience, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0692882
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7341 USD
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
11250 El Camino Real
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2021 dei Local Phone Number
LocalPhoneNumber
410-0266
CY2021 dei Security12g Title
Security12gTitle
Common Stock, Par Value $0.001
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
45310946 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
495925112 shares
CY2021 dei Auditor Firm
AuditorFirmId
199
CY2021 dei Auditor Name
AuditorName
Mayer Hoffman McCann P.C.
CY2021 dei Auditor Location
AuditorLocation
Irvine, California
CY2021Q4 us-gaap Cash
Cash
8983007 USD
CY2020Q4 us-gaap Cash
Cash
2469410 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4571 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4566 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
554217 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
190134 USD
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
13432 USD
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
56870 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
275 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
9612097 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2664385 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87710 USD
CY2020Q4 us-gaap Assets
Assets
2671726 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
146972 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8309 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2021Q4 us-gaap Assets
Assets
9855088 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
897880 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
364340 USD
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
2130 USD
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
17032 USD
CY2021Q4 skye Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
174911 USD
CY2020Q4 skye Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
44087 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
344450 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
61547 USD
CY2021Q4 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
0 USD
CY2020Q4 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
64062 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
375842 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
197564 USD
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
59732 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
38567 USD
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
450000 USD
CY2020Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
0 USD
CY2021Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1524905 USD
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82372 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3912222 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
787199 USD
CY2021Q4 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
0 USD
CY2020Q4 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
52638 USD
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
450000 USD
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 USD
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
931103 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78700 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2021Q4 us-gaap Liabilities
Liabilities
3990922 USD
CY2020Q4 us-gaap Liabilities
Liabilities
2220940 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38896693 USD
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
476108445 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
476108445 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
288074415 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
288074415 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
476108 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
288074 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52644221 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47256163 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38733981 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5864166 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9855088 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2671726 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2931437 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1944411 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4916277 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4344602 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
7847714 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
6289013 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7847714 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-6289013 USD
CY2021 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
21165 USD
CY2020 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-436270 USD
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
117953 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021 us-gaap Interest Expense
InterestExpense
769159 USD
CY2020 us-gaap Interest Expense
InterestExpense
706385 USD
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
3 USD
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
29 USD
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-672368 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-270086 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8520082 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6559099 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2100 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8522182 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6560699 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
406599390 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230746878 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
406599390 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231420973 shares
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8522182 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6560699 USD
CY2021 us-gaap Depreciation
Depreciation
34131 USD
CY2020 us-gaap Depreciation
Depreciation
1872 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
869206 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
302742 USD
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21165 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-436270 USD
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
593802 USD
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
544033 USD
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
117953 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
234531 USD
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-14902 USD
CY2020 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
7032 USD
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
364083 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
37439 USD
CY2021 skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
13432 USD
CY2020 skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
0 USD
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
56595 USD
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-7275 USD
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8309 USD
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
533540 USD
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
130824 USD
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
44087 USD
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
282903 USD
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
0 USD
CY2021 skye Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-9534 USD
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-161295 USD
CY2020 skye Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0 USD
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
166531 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6474888 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6054131 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90866 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7230 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90866 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7230 USD
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
935260 USD
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
854078 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6062774 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6085589 USD
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6999999 USD
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
48533 USD
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11800 USD
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
806 USD
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
592154 USD
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
542523 USD
CY2020 skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
-26563 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4783 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0 USD
CY2020 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
116700 USD
CY2021 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
450000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13079356 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6700822 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6513602 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
639461 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2473976 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1834515 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8987578 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2473976 USD
CY2021Q4 us-gaap Cash
Cash
8983007 USD
CY2020Q4 us-gaap Cash
Cash
2469410 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4571 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4566 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8987578 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2473976 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
44087 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
117459 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
1600 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
1600 USD
CY2021 skye Establishment Of Right Of Use Asset
EstablishmentOfRightOfUseAsset
170606 USD
CY2020 skye Establishment Of Right Of Use Asset
EstablishmentOfRightOfUseAsset
0 USD
CY2021 skye Exercise Of Warrants
ExerciseOfWarrants
0 USD
CY2020 skye Exercise Of Warrants
ExerciseOfWarrants
26250 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
548058 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302742 USD
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
854078 USD
CY2020 skye Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
6085589 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6560699 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
856206 USD
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
935260 USD
CY2021 skye Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
6062774 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4783 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8522182 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5864166 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47256163 USD
CY2021Q4 us-gaap Cash
Cash
8983007 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7847714 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-6289013 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgments as to the appropriate carrying values of equity instruments, derivative liabilities, debt with embedded features, and the valuation of stock based compensation awards, which are not readily apparent from other sources.</span></div>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 USD
CY2019Q4 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
1877938 USD
CY2021 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
CY2021 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
CY2021Q4 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
2484768 USD
CY2021Q4 skye Research And Development Licensed Technology Costs Capitalized To Date
ResearchAndDevelopmentLicensedTechnologyCostsCapitalizedToDate
0 USD
CY2021 skye Class Of Warrant Or Right Warrants Vested And Outstanding
ClassOfWarrantOrRightWarrantsVestedAndOutstanding
154458892 shares
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
38567 USD
CY2021 skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21165 USD
CY2021 skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
0 USD
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
59732 USD
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
501400 USD
CY2020 skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-436270 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
38567 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
90797 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
410603 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
38567 USD
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
174911 USD
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
161546 USD
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
446 USD
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1648 USD
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1510 USD
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
197480453 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021 us-gaap Interest Expense
InterestExpense
769159 USD
CY2020 us-gaap Interest Expense
InterestExpense
706385 USD
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
213540505 shares
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4783 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
869206 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
302742 USD
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1645478 USD
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M13D
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-8522182 USD
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8522182 USD
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
406599390 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8522182 USD
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
406599390 shares
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6560699 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6560699 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230746878 shares
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2020 us-gaap Dilutive Securities
DilutiveSecurities
-345473 USD
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
674095 shares
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6906172 USD
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231420973 shares
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8446034 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-6556280 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-74048 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2819 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8520082 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6559099 USD
CY2021Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
441 USD
CY2020Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
336 USD
CY2021Q4 skye Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
109 USD
CY2020Q4 skye Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
180 USD
CY2021Q4 skye Deferred Tax Assets Research And Development Credits
DeferredTaxAssetsResearchAndDevelopmentCredits
138581 USD
CY2020Q4 skye Deferred Tax Assets Research And Development Credits
DeferredTaxAssetsResearchAndDevelopmentCredits
54324 USD
CY2021Q4 skye Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
33906 USD
CY2020Q4 skye Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
446623 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
83056 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8887647 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7679216 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9507307 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7817112 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9373577 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7590215 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
133730 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
226897 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
30939 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
0 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
102791 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
226897 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
133730 USD
CY2021Q3 skye Lessee Operating Lease Initial Monthly Rent
LesseeOperatingLeaseInitialMonthlyRent
8067 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
226897 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1789217 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1377411 USD
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-475287 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-415249 USD
CY2021 skye Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrant
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant
4445 USD
CY2020 skye Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrant
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant
-72549 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1783362 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1383765 USD
CY2021 skye Effective Income Tax Rate Reconciliation Uncertain Tax Positions Amount
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsAmount
557016 USD
CY2020 skye Effective Income Tax Rate Reconciliation Uncertain Tax Positions Amount
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsAmount
470838 USD
CY2021Q3 skye Lessee Operating Lease Abatement Term
LesseeOperatingLeaseAbatementTerm
P2M
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
36731 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
33925 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
31863 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
64273 USD
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
168514 USD
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
108649 USD
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
785 USD
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
20916 USD
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
22657 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2100 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1783362 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1134173 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
552082 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
687598 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
585812 USD
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
37145 USD
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3721 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1784626 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1134173 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 USD
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 USD
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2021Q4 skye Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
140953 USD
CY2020Q4 skye Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
93888 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
133537 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
57596 USD
CY2021Q4 skye Accrued Board Fees Current
AccruedBoardFeesCurrent
44984 USD
CY2020Q4 skye Accrued Board Fees Current
AccruedBoardFeesCurrent
40625 USD
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
56368 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
5455 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
375842 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
197564 USD
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 skye Lessee Operating Lease Annual Rent Increase Percent
LesseeOperatingLeaseAnnualRentIncreasePercent
0.03
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
30234 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M29D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
97291 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
83093 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
180384 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19312 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
161072 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82372 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78700 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
161072 USD

Files In Submission

Name View Source Status
0001516551-22-000004-index-headers.html Edgar Link pending
0001516551-22-000004-index.html Edgar Link pending
0001516551-22-000004.txt Edgar Link pending
0001516551-22-000004-xbrl.zip Edgar Link pending
amendmentno3totheamendedan.htm Edgar Link pending
consentofindependentregist.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
formofskyerestrictedstocku.htm Edgar Link pending
image_10.jpg Edgar Link pending
image_11.jpg Edgar Link pending
image_12.jpg Edgar Link pending
image_13.jpg Edgar Link pending
image_4.jpg Edgar Link pending
image_5.jpg Edgar Link pending
image_6.jpg Edgar Link pending
image_7.jpg Edgar Link pending
image_8.jpg Edgar Link pending
image_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
noticeofoptionamendment-ex.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
restatedandamendedlicensea.htm Edgar Link pending
Show.js Edgar Link pending
skye-20201231xex321.htm Edgar Link pending
skye-20211231.htm Edgar Link pending
skye-20211231.xsd Edgar Link pending
skye-20211231xex311.htm Edgar Link pending
skye-20211231xex312.htm Edgar Link pending
skye-20211231xex322.htm Edgar Link pending
skye-20211231_cal.xml Edgar Link unprocessable
skye-20211231_def.xml Edgar Link unprocessable
skye-20211231_htm.xml Edgar Link completed
skye-20211231_lab.xml Edgar Link unprocessable
skye-20211231_pre.xml Edgar Link unprocessable
subsidiariesoftheregistran.htm Edgar Link pending